Q2 EPS Estimates for Myomo Cut by Ascendiant Capital Markets

Myomo, Inc. (NYSEAMERICAN:MYO) – Equities research analysts at Ascendiant Capital Markets reduced their Q2 2026 earnings per share estimates for Myomo in a research report issued on Saturday, June 6th. Ascendiant Capital Markets analyst E. Woo now expects that the company will post earnings per share of ($0.11) for the quarter, down from their prior estimate of ($0.10). Ascendiant Capital Markets currently has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Myomo’s current full-year earnings is ($0.28) per share. Ascendiant Capital Markets also issued estimates for Myomo’s Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.34) EPS, Q1 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.07) EPS and Q4 2027 earnings at ($0.03) EPS.

Separately, Craig Hallum reaffirmed a “buy” rating on shares of Myomo in a research report on Tuesday, March 10th. Four analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $7.67.

Myomo Stock Performance

Shares of MYO opened at $1.54 on Thursday. The company has a current ratio of 2.73, a quick ratio of 2.36 and a debt-to-equity ratio of 1.21. The company has a market capitalization of $59.51 million, a price-to-earnings ratio of -4.28 and a beta of 1.47. The stock has a 50 day moving average of $0.90 and a 200 day moving average of $0.88. Myomo has a 12 month low of $0.61 and a 12 month high of $2.95.

Insider Activity

In other news, Director Joseph M. Jr. Manko purchased 30,367 shares of the company’s stock in a transaction on Friday, May 15th. The stock was purchased at an average price of $0.89 per share, with a total value of $27,026.63. Following the completion of the purchase, the director directly owned 2,309,775 shares in the company, valued at approximately $2,055,699.75. This trade represents a 1.33% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Thomas F. Kirk acquired 40,002 shares of Myomo stock in a transaction dated Friday, June 5th. The shares were purchased at an average price of $1.27 per share, for a total transaction of $50,802.54. Following the completion of the transaction, the director directly owned 693,865 shares in the company, valued at approximately $881,208.55. The trade was a 6.12% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have acquired 433,205 shares of company stock valued at $382,868. Corporate insiders own 12.14% of the company’s stock.

Hedge Funds Weigh In On Myomo

Several institutional investors have recently modified their holdings of the company. XTX Topco Ltd bought a new position in shares of Myomo during the 4th quarter valued at about $148,000. AQR Capital Management LLC increased its position in shares of Myomo by 47.8% during the 4th quarter. AQR Capital Management LLC now owns 434,376 shares of the company’s stock valued at $395,000 after purchasing an additional 140,427 shares during the last quarter. State Street Corp increased its position in shares of Myomo by 5.1% during the 4th quarter. State Street Corp now owns 399,853 shares of the company’s stock valued at $364,000 after purchasing an additional 19,563 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Myomo by 103.1% during the 4th quarter. Wells Fargo & Company MN now owns 38,707 shares of the company’s stock valued at $35,000 after purchasing an additional 19,646 shares during the last quarter. Finally, Jane Street Group LLC bought a new position in shares of Myomo during the 4th quarter valued at about $64,000. 44.99% of the stock is currently owned by institutional investors.

About Myomo

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.